Anti-EPHA3 (ifabotuzumab biosimilar) mAb
| Common Name |
KB-004, KB004 |
|---|---|
| Buffer |
Preservative: 0.1% Procline 300 Constituents: 50% Glycerol; PBS, pH 7.4; 0.1% BSA |
| Guarantee | 12 months from date of dispatch |
| Catalog Number | BME100019 |
|---|---|
| Package | 50 μl $80.00 ; 100 μl $160.00 |
| Synonyms | TYRO4, HEK4, ETK1, ETK, EK4, HEK |
| Host Species | Humanized |
| IgG type | IgG1 |
| Clonality | Monoclonal |
| Formulation | Liquid |
| Purification | Purified from cell culture supernatant by affinity chromatography |
| Reactivity | Human |
| Applications | ELISA |
| Recommended Dilutions | ELISA 1:5000-10000 |
| Storage | Store at -20°C (Avoid repeated freezing and thawing) |
| Usage | Research use only |
| Images |
Figure 1. ELISA plate pre-coated by 2 μg/ml (100 μl/well) Human EPHA3, mFc-His tagged protein (PME100045) can bind Anti-EPHA3 Neutralizing antibody in a linear range of 0.13-16.0 ng/ml.
Figure 2. HEK293 cell line transfected with irrelevant protein (B) and human EPHA3 protein (A) were surface stained with anti-EPHA3 neutralizing antibody 1μg/ml (ifabotuzumab) followed by Alexa 488-conjugated anti-human IgG secondary antibody.
|
| Background | Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals. |
| Datasheet | Download | COA | Download |
|---|---|---|---|
| MSDS | Download | ||
简体中文
English
